Cadonilimab + SOX chemotherapy + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Conditions
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Trial Timeline
Aug 14, 2025 → Jul 1, 2031
NCT ID
NCT07023315About Cadonilimab + SOX chemotherapy + Placebo
Cadonilimab + SOX chemotherapy + Placebo is a phase 3 stage product being developed by Akeso for Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07023315. Target conditions include Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07023315 | Phase 3 | Recruiting |
Competing Products
20 competing products in Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma